Overview
Bioceros B.V. is a privately owned biopharmaceutical company, which was founded in April 2003.
Bioceros is one of Europe’s premier providers of GMP-ready protein producing cell lines, based on our proprietary serum-free, suspension CHO platform (named CHOBC ™). Bioceros’ Cell Line Generation capabilities are underscored by its nomination by DSM and Crucell as the first pre-approved Europe-based PER.C6® cell line generation partner. All the Cell Line Generation work that we perform is Quality Controlled.
We have generated cell lines producing proteins ranging from blood proteins and monoclonal antibodies to fusion proteins. For monoclonal antibodies, our services start based on customers wishes, either with cDNA sequences to be expressed or by generation of antibodies in rodents, followed by cloning of the sequences from selected hybridoma’s. Further services include immunoassays, with a particular emphasis on cell based assays.
The people at Bioceros strongly believe that true and close collaboration speeds up selection and development of clients’ most viable drug candidates. Therefore, the programs are designed in a flexible way, and scientists and staff involved in the programs are easily approachable. In addition, due to low overhead cost, our prices are very competitive.
Bioceros exploits its validated technology platform and its extensive pre-clinical antibody development expertise to select and develop novel functional effective proprietary therapeutic monoclonal antibodies.
Bioceros is dedicated to improve the lives of patients by providing opportunities for real market growth.
